DENISE CORRIVEAU: Open Payments
NPI 1902420938 · SAN DIEGO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,463 in 71 payments from 16 companies in 2025. Trend: 2023 $1,639 · 2024 $3,940 · 2025 $1,463
Food & beverage: $1,463
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $310 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $217 |
| Janssen Biotech, Inc. | 12 | $213 |
| Regeneron Healthcare Solutions, Inc. | 7 | $200 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 11 | $189 |
| GENZYME CORPORATION | 3 | $110 |
| Lilly USA, LLC | 1 | $32 |
| Braintree Laboratories, Inc. | 1 | $30 |
| AstraZeneca Pharmaceuticals LP | 1 | $29 |
| Ipsen Biopharmaceuticals, Inc | 1 | $22 |
Products named: DUPIXENT, TREMFYA, ENTYVIO, XIFAXAN, LINZESS, RINVOQ, CREON, OMVOH.
Industry payments across CA — which companies pay providers there.
